Brief: Cullinan Oncology Announces Updated Phase 1/2a Data for CLN-081 In NSCLC EGFR Exon 20 Patients

Cullinan Therapeutics

16/12/2021 12:13

Dec 16 (Reuters) - Cullinan Oncology Inc  CGEM.O :
    * CULLINAN ONCOLOGY ANNOUNCES UPDATED PHASE 1/2A DATA
FOR CLN-081
IN NSCLC EGFR EXON 20 PATIENTS
    * CULLINAN ONCOLOGY INC - CLN-081 CONTINUES TO DEMONSTRATE A
DIFFERENTIATED CLINICAL PROFILE AT RECOMMENDED PHASE 2 DOSE OF
100MG BID
    * CULLINAN ONCOLOGY INC - CONTINUED HIGH RESPONSE RATE WITH
FAVORABLE SAFETY AND TOLERABILITY PROFILE OBSERVED IN HEAVILY
PRE-TREATED PATIENTS AT 100MG BID
    * CULLINAN ONCOLOGY INC - ENCOURAGING DURABLE RESPONSES AND
PROGRESSION FREE SURVIVAL AT 100MG BID

Source text for Eikon:  ID:nGNX7X2RFM 
Further company coverage:  CGEM.O 

 ((Reuters.Briefs@thomsonreuters.com;))